FindTrial
Sign In

Case series:CART cells

11 trials

Sponsors

The Fifth Hospital Affiliated to Zhongshan University, He'nan Province Cancer Hospital, West China Hospital, Sichuan University, Qilu Hospital of Shandong University, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Conditions

Breast CancerHepatocellular carcinomaRefractory Aggressive Non-Hodgkin Lymphoma (NHL)Relapsed / refractory thyroid cancercolorectal cancergastric cancerpancreatic cancerprostatic cancer (CaP)

Early Phase 1

Chimeric Antigen Receptor T Cells (CART) Therapy in colorectal cancer
Active, not recruitingChiCTR1900022606
The Fifth Hospital Affiliated to Zhongshan Universitycolorectal cancer
Start: 2019-04-18Updated: 2020-04-20
Chimeric Antigen Receptor T Cells (CART) Therapy for gastric cancer
RecruitingChiCTR1900025007
Qilu Hospital of Shandong Universitygastric cancer
Start: 2019-08-09Updated: 2019-08-27
Chimeric Antigen Receptor T Cells (CART) Therapy in colorectal cancer
RecruitingChiCTR1900025321
The Second Affiliated Hospital of Chongqing Medical Universitycolorectal cancer
Start: 2019-08-30Updated: 2019-08-27
Chimeric Antigen Receptor T Cells (CART) Therapy in prostatic cancer (CaP)
Active, not recruitingChiCTR1900027577
The Fifth Hospital Affiliated to Zhongshan Universityprostatic cancer (CaP)
Start: 2019-11-28Updated: 2019-11-25
MUC-1 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Breast Cancer
Active, not recruitingChiCTR1900027907
The Fifth Hospital Affiliated to Zhongshan UniversityBreast Cancer
Start: 2019-12-31Updated: 2019-12-10
Phase I single arm and open clinical study of gpc3-car-ori2 modified T cells in the treatment of failed advanced HCC
RecruitingChiCTR1900028121
The Central Hospital of Lishui CityHepatocellular carcinoma
Start: 2019-07-02Updated: 2019-12-16

Phase 1

Clinical Study for Safety and Efficacy of (TSHR+CD19) CART Cell in the Treatment of Refractory Thyroid Cancer
Active, not recruitingChiCTR1900022607
The Fifth Hospital Affiliated to Zhongshan UniversityRelapsed / refractory thyroid cancer
Start: 2019-04-19Updated: 2019-04-23
(MUC-1+CD19) targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Pancreatic Cancer
Active, not recruitingChiCTR1900022608
The Fifth Hospital Affiliated to Zhongshan Universitypancreatic cancer
Start: 2019-04-19Updated: 2019-04-23
Clinical Study for Safety and Efficacy of dPD-1(TSHR+CD19) CART Cell in the Treatment of Refractory Thyroid Cancer
Active, not recruitingChiCTR1900022620
He'nan Province Cancer HospitalRelapsed / refractory thyroid cancer
Start: 2019-04-19Updated: 2019-04-23
hCD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non-Hodgkin's lymphoma
Active, not recruitingChiCTR1900022622
West China Hospital, Sichuan UniversityRefractory Aggressive Non-Hodgkin Lymphoma (NHL)
Start: 2019-04-18Updated: 2019-04-23
immunocyte Therapy in Pancreatic Cancer
RecruitingChiCTR1900025185
Sir Run Run Shaw Hospital, Zhejiang University School of Medicinepancreatic cancer
Start: 2019-05-21Updated: 2019-08-27

Related Papers

Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2025-05-285 citations
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
Journal of Clinical Oncology2021-05-2011 citations